Positioning of proteasome inhibitors in therapy of solid malignancies

por Roeten, Margot S. F., Cloos, Jacqueline, Jansen, Gerrit
Publicado 2017

(Immuno)proteasomes as therapeutic target in acute leukemia

por Cloos, Jacqueline, Roeten, Margot SF, Franke, Niels E, van Meerloo, Johan, Zweegman, Sonja, Kaspers, Gertjan JL, Jansen, Gerrit
Publicado 2017

1,3,4-Oxadiazole and 1,3,4-Thiadiazole Nortopsentin Derivatives against Pancreatic Ductal Adenocarcinoma: Synthesis, Cytotoxic Activity, and Inhibition of CDK1

por Carbone, Daniela, Pecoraro, Camilla, Panzeca, Giovanna, Xu, Geng, Roeten, Margot S. F., Cascioferro, Stella, Giovannetti, Elisa, Diana, Patrizia, Parrino, Barbara
Publicado 2023

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells

por Roeten, Margot S.F., van Meerloo, Johan, Kwidama, Zinia J., ter Huizen, Giovanna, Segerink, Wouter H., Zweegman, Sonja, Kaspers, Gertjan J.L., Jansen, Gerrit, Cloos, Jacqueline
Publicado 2021

P329: HIGH IMMUNOPROTEASOME ACTIVITY AS NOVEL INDICATOR FOR SENSITIVITY TO BORTEZOMIB-CONTAINING CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM CHILDREN’S ONCOLOGY GROU...

por Roeten, Margot, van Dijk, Suzanne, van Meerloo, Johan, Kwidama, Zinia, Jenkins, Gaya, Teachey, David, Devidas, Meenakshi, Loh, Mignon, Kaspers, Gertjan, Zweegman, Sonja, Jansen, Gerrit, Horton, Terzah, Cloos, Jacqueline
Publicado 2023